Glenmark Pharmaceuticals Inc. USA (Glenmark), based in New Jersey, has been held accountable for $25 million to resolve allegations that the company fixed drug prices. The drug in question is pravastatin, used to treat high cholesterol and triglyceride levels. Between 2013 and 2015, Glenmark allegedly made investments and received monies entirely in breach of the Anti-Kickback Statute in promoting the drug alongside other pharmaceutical companies. “At a time when excessive drug costs are already imposing unprecedented burdens on our country’s vulnerable citizens, an illegal conspiracy to fix t…